A Pilot Study of PET Imaging of Solid Tumors Using Radioactive Iodine-Labeled Hu3F8

Full Title

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Purpose

3F8 is an antibody that attaches to neuroblastoma cells and helps focus a patient¿s own immune system ¿ especially white blood cells ¿ to attack neuroblastoma cells. Conventional 3F8 is made from mouse cells. Humanized 3F8 (Hu3F8) is made to be more like the human immune system than a mouse¿s immune system, so it may be associated with fewer side effects in patients than standard mouse-derived 3F8. Memorial Sloan Kettering has been assessing the use of Hu3F8 in patients with neuroblastoma that has returned despite prior treatment or has a high risk of returning.

In this study, researchers are evaluating how Hu3F8 travels throughout the body and to tumors by attaching it to radioactive iodine and observing its distribution in the body using PET scanning (positron emission tomography), which tracks where the radioactive iodine goes. The radioactive iodine being used in this study is called 124I. Researchers want to see if 124I-Hu3F8 can be safely used to deliver radiation to tumor cells in patients with neuroblastoma and other cancers that are recognized by the Hu3F8 antibody.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have neuroblastoma or another cancer that is recognized by Hu3F8 (such as melanoma or sarcoma), and has returned despite treatment or has stopped responding to treatment.
  • This study is for patients ages 3 to 90.

For more information about this study and to inquire about eligibility, please contact Dr. Shakeel Modak at 212-639-7623.

Protocol

13-147

Phase

Pilot

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Locations